Chronic obstructive pulmonary disease (
COPD) is a life-threatening inflammatory respiratory disorder, often induced by cigarette
smoke (CS) exposure. The development of effective
therapies is impaired by a lack of understanding of the underlining mechanisms.
Tumor necrosis factor-related apoptosis-inducing
ligand (TRAIL) is a
cytokine with inflammatory and apoptotic properties. We interrogated a mouse model of CS-induced experimental
COPD and human tissues to identify a novel role for TRAIL in
COPD pathogenesis. CS exposure of wild-type mice increased TRAIL and its receptor
messenger RNA (
mRNA) expression and
protein levels, as well as the number of TRAIL(+)CD11b(+) monocytes in the lung. TRAIL and its receptor
mRNA were also increased in human
COPD. CS-exposed TRAIL-deficient mice had decreased
pulmonary inflammation, pro-inflammatory mediators,
emphysema-like alveolar enlargement, and improved lung function. TRAIL-deficient mice also developed spontaneous small airway changes with increased epithelial cell thickness and
collagen deposition, independent of CS exposure. Importantly, therapeutic neutralization of TRAIL, after the establishment of early-stage experimental
COPD, reduced
pulmonary inflammation,
emphysema-like alveolar enlargement, and small airway changes. These data provide further evidence for TRAIL being a pivotal inflammatory factor in
respiratory diseases, and the first preclinical evidence to suggest that therapeutic agents that target TRAIL may be effective in
COPD therapy.